Neurocrine Biosciences, Inc. (NBIX) Institutional Ownership & Insider Trading

774 institutions reported holding Neurocrine Biosciences, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 40 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NBIXNeurocrine Biosciences, Inc.Follow NBIX — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 14.5B
P/E TTM: 20.9
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

774 institutions held 99.5% of the shares. Across filers that reported both quarters, shares held changed +0.2%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	774	101	+0.2%	290	121	205	49
Mar 26	689	100	+3.0%	274	55	192	96
Dec 25	716	99	-3.1%	248	89	198	24
Sep 25	628	102	+3.7%	187	90	194	36
Jun 25	574	99	+2.8%	206	60	196	58
Mar 25	569	94	-0.2%	159	54	233	71
Dec 24	583	94	+0.2%	189	68	189	62
Sep 24	561	93	-2.7%	222	50	177	74

Neurocrine Biosciences, Inc. — questions

Who owns Neurocrine Biosciences, Inc. stock?: 774 institutions reported Neurocrine Biosciences, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (13.5%), JPMORGAN CHASE & CO (6.3%), Dodge & Cox (5.5%).
Are Neurocrine Biosciences, Inc. insiders buying or selling?: 40 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Neurocrine Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.